Beta-Amyloid (1-42), H6A Mutant
Beta-amyloid (A-beta) has been long reported as the major constituent of amyloid plaques in the brains of Alzheimer’s patients, and is believed by many to be the cause of Alzheimer’s Disease (AD). AD is the most common neurodegenerative disease and afflicts more than 10% of the population over 65. Recombinantly expressed and sourced from E. coli, rPeptide’s high quality beta-amyloid products offer batch-to-batch consistency and ultrapure starting material for your research needs. The TFA (trifluoro-acetic acid) counter-ion is a peptide which was lyophilized in a final solution containing TFA and is a popular choice for researchers wishing to build on previous studies using this same product.
$100.00 – $575.00
-
Product Details
- Physical State: White lyophilized powder
- Temperature Storage: -20°C
- Temperature Shipping: Ambient
- Sequence:
D A E F R A D S G Y E V H H Q K L V F F A E D V G S N K G A I I G L M V G G V V I A
- Source: Recombinant. A DNA sequence encoding the human beta-amyloid (1-42) sequence, with a point mutation (H6A), was expressed in E. coli
- Purity: >97% by Mass Spec.
- Molecular Mass: 4,448 Da theoretical
-
References
1. Yankner, B., et al., (1990) Science, 250 : 279-282
2. Stine, W., et al., (2003) J. Biol. Chem, 278 : 11612-11622
3. Frank, R., et al., (2003) Neurobiology of Aging, 24 : 521-536
4. Gericke, C., et al., (2020) Front. Immunol., 11 : 1029 -
Publications
Reciprocal modulation of Aβ42 aggregation by copper and homocysteine.
Front Aging Neurosci.; https://doi.org/10.3389/fnagi.2014.00237.
